We contribute to medical care through innovative drug discovery using the technologies of cell-free membrane protein preparation and non-canonical amino acid incorporation into target proteins.




CompanyLiberoThera Co., Ltd.
Registered OfficeNihonbashi Life Science Building 7, 8F
1-9-10 Nihonbashi-horidomecho, Chuo-ku, Tokyo 103-0012, Japan
TIP LaboratoryTokyo Medical and Dental University/ Bldg.8 TIP LAB #516
1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, JAPAN
EstablishmentApril 3, 2018
CEOToru Kanke, Ph.D.
BusinessDrug discovery targeting on membrane proteins and drug discovery services
Capital100,000,000 yen(As of April 1, 2022)
Number of Officers & Employees13(As of April 1, 2022)
Main BankMUFG Bank, Ltd., Mizuho Bank, Ltd.
Corporate History
2017 JanuaryLiberoThera’s founders took second place at BRAVE Pitch Contest.
2017 JanuaryLiberoThera’s founders were awarded a Prize of Mitsui Fudosan Life Science.
2017 OctoberJapan Science and Technology Agency (JST) accepted LiberoThera’s founders’ proposal “Acceleration of novel drug development using cell-free membrane protein preparation technology and non-canonical amino acid incorporation technology”.
2018 AprilFounded at Nihonbashi-honcho, Chuo-ku, Tokyo.
2018 JulyNew Energy and Industrial Technology Development Organization (NEDO) accepted LiberoThera’s proposal for “Commercialization Support Program for Seed-stage Technology-based Startups (NEDO-STS) “.
2018 NovemberLiberoThera opened an office in Yokohama (Tsurumi Office)
2019 FebruaryLiberoThera opened a research laboratory in Tokyo (Nihonbashi Laboratory)
2021 copyright LiberoThera Co., Ltd.